Key Highlights
• Leadership team in place: Following appointment as Nigel Lange as CEO, key recent hires include a Chief Medical Officer, Head of Medical Affairs, Director of Access Reimbursement, Economics and Assessment and Director of Clinical development
• Finalising data package for HDE submission: Currently finalising an updated dataset which involves a more recent data cut-off point, to support its HDE application to the FDA
• Targeting hospitals in Greater London in the near-term: Pushing forward with launch preparation activities throughout Europe including establishing the Osprey registry
• Additional sales in New Zealand: Following OncoSil’s first ever commercial sale, OncoSil has achieved further sales in New Zealand
• Cash position: Cash balance of $15.3 million as at 31 March 2021
- Forums
- ASX - By Stock
- Ann: Appendix 4C - quarterly
Key Highlights• Leadership team in place: Following appointment...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
|
|||||
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.40M |
Open | High | Low | Value | Volume |
1.2¢ | 1.2¢ | 1.1¢ | $65.61K | 5.632M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 6553895 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 1917493 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 6553895 | 0.011 |
15 | 11480500 | 0.010 |
25 | 14580403 | 0.009 |
6 | 6975000 | 0.008 |
12 | 4797857 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 1917493 | 5 |
0.013 | 11116832 | 6 |
0.014 | 7811217 | 11 |
0.015 | 8500000 | 3 |
0.016 | 3766668 | 2 |
Last trade - 15.50pm 16/08/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |